Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the ...

<?xml encoding="utf-8" ?> A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a ...

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.6%. The iShares Biotechnolog ...

Learn more Moderna (MRNA) and other vaccine developers were up on Friday after The New York Times reported that the National Institutes of Health is part of a public-private partnership to accelerate ...

U.S. stocks closed higher on Friday, led by a tech-sector rebound, with the Dow surging more than 400 points and all three major indexes ...

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point Sanofi ...

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.

Moderna ( MRNA) shares surged just over 14% on Friday, ending at $225.00 after rising $28.00 from the previous session's ...

Nine of 11 sectors rose, powering the S&P higher despite semiconductor weakness. Small-caps, though, posted a fifth straight ...